Overview

A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed